HCA Warning, Leqembi SubQ, FTC Insulin

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are particularly urgent given the convergence of market signals and policy shifts.

MarcusSame here. We're looking at HCA's profit warning and what it signals for healthcare access. Then the subcutaneous Leqembi approval and its HEOR implications. And the FTC settlement with CVS Caremark over insulin pricing.

SaraThat second one on Leqembi is critical — we've seen the IV version struggle with cost-effectiveness, and now the subcutaneous route might change the calculus on administration costs.

MarcusExactly. Let's get into it.

MarcusHCA's profit warning is striking. They're citing lower patient volumes and rising costs, specifically increased uncompensated care and higher labor expenses. This isn't just a financial hiccup—it's a structural strain signal on US healthcare access, particularly for vulnerable populations.

SaraAbsolutely, and what's concerning is the timing. With CMS Part D implementation still unfolding, this suggests the system may be absorbing costs differently than anticipated. The uncompensated care angle points directly to payer-provider financial friction.

MarcusThat connects to something I keep coming back to: when safety-net hospitals face margin pressure, we often see reduced capacity for complex therapies. That creates downstream access barriers even for well-reimbursed products.

SaraExactly. And from the payer side, this could accelerate existing trends toward step therapy protocols for high-cost drugs. If HCA's margins are squeezed, we might see more aggressive utilization management across their network.

MarcusI wonder if that's the full picture though. The labor cost component suggests broader workforce issues that aren't easily solved by pricing strategies alone. This feels like a system-level stress test.

SaraThat's fair, though I think payers would see this as a budget impact multiplier. When providers struggle, it often translates to higher administrative costs for payers managing those networks. The real question is whether this is cyclical or structural.

MarcusWe'll be watching how this plays out with Q2 earnings. If other hospital systems follow suit, it could reshape payer-provider negotiations for innovative therapies.

MarcusThe subcutaneous Leqembi approval is fascinating. Same Phase 3 efficacy data as IV, but now with a subcutaneous formulation. That changes the administration calculus significantly—no more infusion centers, no nursing time, potentially lower administration costs.

SaraWhich immediately raises HEOR questions. The cost-effectiveness models for the IV version were already marginal at best. If we can reduce administration costs by 20-30% while maintaining efficacy, that could shift the ICER calculation substantially.

MarcusRight, and what strikes me here is the real-world evidence opportunity. Post-approval, we'll need to track adherence patterns. Subcutaneous administration might improve persistence, which could translate to better outcomes and cost offsets.

SaraBut I'd push back slightly on that. The evidence base still relies on the same CLARITY-AD trial data. We don't have RWE yet showing whether subcutaneous actually improves adherence in real-world settings. That's a methodological gap.

MarcusThat's a valid point. The FDA approval was based on pharmacokinetic bridging, not clinical outcomes. So HEOR teams will need to generate new real-world data to support value propositions, especially for payers skeptical of the same efficacy claim.

SaraExactly. And this creates a new evidence generation imperative. Manufacturers might need to fund prospective studies comparing real-world adherence between formulations, which adds to development timelines.

MarcusThe patient experience angle is compelling too. Fewer clinic visits could mean reduced caregiver burden, which has its own quality-of-life implications. But payers will need that quantified in their value frameworks.

SaraAgreed. The key will be whether the administration cost savings offset the drug's high price tag. If not, we might see similar coverage challenges as the IV version, just with a different evidence package.

MarcusThe FTC settlement with CVS Caremark is significant—$20 million and mandatory pricing practice changes over insulin anti-competitive claims. This signals heightened scrutiny of PBM practices, particularly around rebate structures and formulary placement.

SaraAbsolutely. The $20 million penalty is substantial, but more importantly, the behavioral changes required could disrupt long-standing rebate models. If PBMs can't use formulary exclusivity to extract rebates, insulin pricing dynamics could shift dramatically.

MarcusThat connects to the broader IRA context too. With Medicare Part D now negotiating insulin prices, this settlement could accelerate transparency around actual acquisition costs versus list prices.

SaraAnd from the payer side, this might reduce the pass-through costs that ultimately hit formularies. If rebate practices change, we could see more predictable net costs for health plans managing insulin utilization.

MarcusI wonder though whether this is just the tip of the iceberg. The FTC's focus on insulin suggests they're looking at other high-cost therapeutic areas next. Biosimilars and oncology drugs could be in the crosshairs.

SaraThat's precisely what I'm tracking. The precedent here could reshape how manufacturers engage with PBMs on contract terms. We might see more value-based agreements tied to transparent pricing.

MarcusThe competition angle is key too. By restricting anti-competitive practices, the FTC aims to foster more market competition. That could benefit biosimilar entry and generic substitution in insulin markets.

SaraWhich ultimately benefits patients and payers through lower net costs. But the implementation timeline for these practice changes will be critical to monitor.

MarcusICER's expansion of early-phase scientific advice is a strategic shift. New offerings for ultra-orphan therapies and digital therapeutics respond to growing demand from manufacturers for early value strategy input.

SaraAnd it's interesting timing. With more ultra-orphan therapies entering development, manufacturers need early HTA signals to de-risk investment decisions. ICER's expanded program could fill that evidence generation gap.

MarcusRight, but what strikes me is the digital therapeutics inclusion. That's a recognition of emerging evidence challenges for non-drug interventions. HEOR teams will need new methodologies to assess these.

SaraI'd frame it slightly differently though. Payers have struggled with digital health evidence frameworks. ICER's involvement could standardize that, but we'll need to see if their assessments actually translate to coverage decisions.

MarcusThat's a fair point. The challenge will be aligning early scientific advice with later HTA submissions. If the advice doesn't influence final assessments, manufacturers may question the value of the process.

SaraExactly. And for ultra-orphan therapies, the budget impact question looms large. Even with strong efficacy, payers need to understand the opportunity cost of treating ultra-rare conditions.

MarcusThe expansion also signals ICER's evolution beyond traditional cost-effectiveness analyses. They're moving upstream to influence development pathways, which could reshape how evidence is generated from the outset.

SaraWhich ultimately benefits patients by ensuring therapies address unmet needs. But we'll be watching how these new services impact ICER's credibility with payers and manufacturers alike.

SaraA lot to think about today. I'll be watching how HCA's financial pressures ripple through provider networks and whether that triggers broader access constraints.

MarcusSame — and for me the thread running through today is the convergence of financial pressures and evidence evolution. We're seeing system stress points that demand new value frameworks.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.